or search for allinseo plug in" Body Health Advisor » Blog Archive » Advice on Health and Body Matters

Dietary Supplements Worth $1.3 Million Condemned and Forfeited to the United States Under Consent Decree

FDA alleged ‘Body-building’ products contained unapproved food additive, new dietary ingredient and these products will now be destroyed

The U.S. District Court for the Eastern District of Michigan, Southern Division, today entered a consent decree that condemns and forfeits to the United States for destruction about $1.3 million worth of dietary supplements.

“The court order is the result of efforts by the federal government to protect consumers from products for which there is inadequate information to assure that they do not present a significant or unreasonable risk of illness or injury,” said Michael Chappell, FDA’s acting associate commissioner for regulatory affairs. “It shows that the agency is prepared to use the necessary legal means to keep such products out of the marketplace.”

At the request of the FDA, U.S. Marshals seized more than 23,300 bottles of three dietary supplement products distributed by LG Sciences LLC, of Brighton, Mich. The seized products were marketed for use by body builders and distributed on the Internet and in retail stores under the names “Methyl 1-D,” “Methyl 1-D XL,” and “Formadrol Extreme XL.”

Based on laboratory tests, the FDA determined that the products contain one or more unapproved food additives and/or new dietary ingredients for which there is inadequate information to assure that the ingredients do not present a significant or unreasonable risk of illness or injury. Specifically, the condemned Methyl 1-D and Methyl 1-D XL contained 1,4,6-androstatriene-3,17-dione, also known as “ATD” or 1,4,6-etioallocholan-dione. The condemned Formadrol Extreme XL contained ATD and 3,6,17-androstenetrione (also known as “6-OXO”). Both of these substances are steroids that inhibit the activity of the enzyme aromatase and may be found in dietary supplements promoted to boost testosterone levels.

The FDA has no scientific information concerning the safety of the condemned products or their ingredients and, thus, cannot determine whether they represent a hazard to consumers. Under the circumstances, consumers who use or have used the products should discuss their use with their health care professionals.
The FDA also recommends that consumers consult their health care professionals if they have experienced any adverse events that they suspect are related to the products’ use.
Health care professionals and consumers may report serious adverse events (side effects) or product quality problems with the use of this product to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, fax or phone.

  • Online
  • Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm and mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787
  • Fax: (800) FDA-0178
  • Phone: (800) FDA-1088

RSS Feed for FDA News Releases

-

Technorati Tags: ,

Tags: , , ,

Leave a Reply

  • Kombiglyze XR as a treatment for type 2 diabetes in adults approved
    Bristol-Myers, AstraZeneca Receive FDA Approval For Diabetes Drug. The AP (11/5) reported, “Drug makers Bristol-Myers Squibb Co. and AstraZeneca PLC said Friday that they received US marketing approval for a once-a-day diabetes drug that combines the starter diabetes drug metformin with the companies’ newer drug Onglyza.” The Food and Drug […]
  • Type 2 Diabetes is increasing in China
    Global research and advisory firm Decision Resources has predicted that the Chinese type 2 diabetes market will grow from $1.4 billion in 2009 to $2.5 billion in 2014. According to the Emerging Markets report entitled Type 2 Diabetes in China, this growth is attributed to an increasing drug-treated population, expanding medical insurance coverage and the [.. […]
  • Avastatin for Breast cancer
    Roche Stands To Lose Substantial Sales Should Regulatory Bodies Revoke License For Avastin. Dow Jones Newswire(12/8, Mijuk) reported that should FDA and European regulators revoke the license for Avastin (bevacizumab) as a treatment for breast cancer, then the drug’s maker, Roche Holding AG, may stand to lose more than one billion Swiss francs in sales […]
  • FDA: Tainted products marketed as dietary supplements potentially dangerous
    Agency working with trade associations to increase company vigilance and protect public In a letter sent today to dietary supplement manufacturers, the U.S. Food and Drug Administration expressed concern about undeclared or deceptively labeled ingredients in products marketed as dietary supplements. These substances include the active ingredients in FDA-a […]
H1N1 Fraudulent Products update







Tai Chi WeightLoss